Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RVT-503
- Development stage
- Discontinued
- Lead developer
- Dermavant Sciences
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
RVT-503 (also known as DMVT-503) is an investigational small molecule inhibitor of diacylglycerol O-acyltransferase 1 (DGAT1) that was developed by Dermavant Sciences, a subsidiary of Roivant Sciences. The drug was designed as a topical treatment for acne vulgaris, targeting the enzymatic pathway responsible for the final step of triglyceride synthesis. By inhibiting DGAT1 in the skin, RVT-503 aimed to reduce sebum production and modify its composition, thereby addressing one of the primary drivers of acne pathogenesis. In 2022, Roivant Sciences announced the discontinuation of the RVT-503 program as part of a strategic pipeline reprioritization to focus resources on the commercial launch of tapinarof (VTAMA) and other late-stage clinical assets.
Beyond the preview
Go deeper on RVT-503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RVT-503.